HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trans Fatty Acids In Infant Formulas Should Be Limited, U.S. Tells Codex

This article was originally published in The Tan Sheet

Executive Summary

A U.S. delegation urges Codex Alimentarius to curb the amount of trans fatty acids allowed in infant formula because of safety concerns in a draft position paper on Codex' proposed standards for infant formula.

You may also be interested in...

Codex Health Claims "Proportional" Substantiation "Confusing" - U.S. Draft

A substantiation model for health-related claims for food - which would allow different levels of supporting evidence based on the type of claim - is inappropriate, the U.S. delegation to the Codex Committee on Food Labeling says in a draft position paper presented for public comment May 1.

Trans fatty acids

Food marketers would be required to disclose the trans fatty acids content of products in the "Nutrition Facts" panel under an FDA proposed rule expected to be published in the Nov. 17 Federal Register. The levels of trans fat also would be considered when attempting to meet the requirements for claims regarding "low saturated fat" and "reduced saturated fat," as well as "lean," "extra lean" and cholesterol claims. Products containing more than 4 g saturated and trans fat combined per serving additionally would be prohibited from making health claims, such as the approved claim for calcium and osteoporosis. The public comment period on the proposal will run for 90 days

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts